» Articles » PMID: 38858382

Alantolactone Attenuates High-fat Diet-induced Inflammation and Oxidative Stress in Non-alcoholic Fatty Liver Disease

Overview
Journal Nutr Diabetes
Date 2024 Jun 10
PMID 38858382
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Nonalcoholic fatty liver disease (NAFLD) is a chronic disease with an increasing incidence, which can further develop into liver fibrosis and hepatocellular carcinoma at the end stage. Alantolactone (Ala), a sesquiterpene lactone isolated from Asteraceae, has shown anti-inflammatory effects in different models. However, the therapeutic effect of Ala on NAFLD is not clear.

Methods: C57BL/6 mice were fed a high-fat diet (HFD) to induce NAFLD. After 16 weeks, Ala was administered by gavage to observe its effect on NAFLD. RNA sequencing of liver tissues was performed to investigate the mechanism. In vitro, mouse cell line AML-12 was pretreated with Ala to resist palmitic acid (PA)-induced inflammation, oxidative stress and fibrosis.

Results: Ala significantly inhibited inflammation, fibrosis and oxidative stress in HFD-induced mice, as well as PA-induced AML-12 cells. Mechanistic studies showed that the effect of Ala was related to the induction of Nrf2 and the inhibition of NF-κB. Taken together, these findings suggested that Ala exerted a liver protective effect on NAFLD by blocking inflammation and oxidative stress.

Conclusions: The study found that Ala exerted a liver protective effect on NAFLD by blocking inflammation and oxidative stress, suggesting that Ala is an effective therapy for NAFLD.

Citing Articles

Natural Bioactive Compounds in the Management of Type 2 Diabetes and Metabolic (Dysfunction)-Associated Steatotic Liver Disease.

Ciobarca D, Catoi A, Gavrilas L, Banc R, Miere D, Filip L Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40006091 PMC: 11859434. DOI: 10.3390/ph18020279.


Probiotic intervention and exercise mitigate inflammation and histopathological alterations in the liver of wistar rats on a high-fat diet.

Pekand M, Gholami M, Abednatanzi H, Ghazalian F Mol Biol Rep. 2025; 52(1):215.

PMID: 39923222 DOI: 10.1007/s11033-025-10320-w.

References
1.
Liu X, Bian L, Duan X, Zhuang X, Sui Y, Yang L . Alantolactone: A sesquiterpene lactone with diverse pharmacological effects. Chem Biol Drug Des. 2021; 98(6):1131-1145. DOI: 10.1111/cbdd.13972. View

2.
Cobbina E, Akhlaghi F . Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metab Rev. 2017; 49(2):197-211. PMC: 5576152. DOI: 10.1080/03602532.2017.1293683. View

3.
Lee D, Park J, Lee Y, Han J, Lee D, Kwon S . SQSTM1/p62 activates NFE2L2/NRF2 via ULK1-mediated autophagic KEAP1 degradation and protects mouse liver from lipotoxicity. Autophagy. 2020; 16(11):1949-1973. PMC: 7595589. DOI: 10.1080/15548627.2020.1712108. View

4.
Amar J, Chabo C, Waget A, Klopp P, Vachoux C, Bermudez-Humaran L . Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment. EMBO Mol Med. 2011; 3(9):559-72. PMC: 3265717. DOI: 10.1002/emmm.201100159. View

5.
Ipsen D, Lykkesfeldt J, Tveden-Nyborg P . Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell Mol Life Sci. 2018; 75(18):3313-3327. PMC: 6105174. DOI: 10.1007/s00018-018-2860-6. View